1.4- (5 - {(1R) -1- [5- (3-chlorophenyl) isoxazol-3-yl] ethoxy} -4-methyl-4H-1,2,4-triazol-3-yl) pyridine in crystalline form. ! 2.4- (5 - {(1R) -1- [5- (3-chlorophenyl) isoxazol-3-yl] ethoxy} -4-methyl-4H-1,2,4-triazol-3-yl) pyridine in the crystalline form according to claim 1, characterized by a powder X-ray diffraction pattern showing, in essence, the following main peak with a value of d:! The interplanar spacing d (Å) is 4.0! 3.4- (5 - {(1R) -1- [5- (3-chlorophenyl) isoxazol-3-yl] ethoxy} -4-methyl-4H-1,2,4-triazol-3-yl) pyridine in the crystalline form according to claim 1, characterized by a powder X-ray diffraction pattern, showing essentially the following main peaks with d values:! The value of the interplanar distance d (Å) 4.0 5.08 5.72 6.35! 4. 4- (5 - {(1R) -1- [5- (3-chlorophenyl) isoxazol-3-yl] ethoxy} -4-methyl-4H-1,2,4-triazol-3-yl) pyridine in the crystalline form according to claim 1, characterized by a powder X-ray diffraction pattern, showing essentially the following main peaks with d values:! The value of the interplanar distance d (Å) 4.0 5.08 5.72 6.21 6.35 11.41 12.63! 5.4- (5 - {(1R) -1- [5- (3-chlorophenyl) isoxazol-3-yl] ethoxy} -4-methyl-4H-1,2,4-triazol-3-yl) pyridine in crystalline form according to claim 2, characterized by a powder X-ray diffraction pattern, essentially as shown in FIG. ! 6. The compound according to any one of claims 1 to 5 for use in therapy. ! 7. A pharmaceutical composition comprising a compound according to any one of claims 1 to 5 in a mixture with at least one pharmaceutically acceptable excipient. ! 8. The use of a compound according to any one of claims 1 to 5 as an active ingredient in the manufacture of a medicament for the prevention or treatment of1. 4-(5-{(1R)-1-[5-(3-хлорфенил)изоксазол-3-ил]этокси}-4-метил-4H-1,2,4-триазол-3-ил)пиридин в кристаллической форме. ! 2. 4-(5-{(1R)-1-[5-(3-хлорфенил)изоксазол-3-ил]этокси}-4-метил-4Н-1,2,4-триазол-3-ил)пиридин в кристаллической форме по п.1, характеризую
